Danaher Corporation vs S&P Global Inc — how do they compare? Danaher Corporation trades at $197.72 (market cap $140.88B), while S&P Global Inc trades at $439.77 (market cap $129.91B). The key difference: Danaher Corporation and S&P Global Inc are close in size by market cap, and S&P Global Inc pays the higher dividend (0.88%). Which is the better fit depends on your goals.
| DHR | SPGI | |
|---|---|---|
Market Cap | $140.88B | $129.91B |
Sector | Health | Financials |
52-Week High | $242.05 | $534.79 |
52-Week Low | $161.91 | $370.42 |
Enterprise Value | $153.66B | $141.87B |
Dividend Yield | 0.8% | 0.88% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
S&P Global (SPGI) trades at $437.84, up 1.7% today, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $15.34B and net income margin of 30.36%. Recent developments include the completion of the Mobility Global spinoff and a strategic shift toward AI-driven market intelligence solutions, positioning the company for sustained growth amid favorable debt issuance trends.
The outlook for SPGI is positive, driven by margin expansion targets and increasing API usage linked to AI adoption. Key risks include interest rate sensitivity in the ratings segment and competitive pressures. With 85.7% of analysts rating it a Buy and a consensus price target of $532.38, the stock offers significant upside potential, though investors should monitor execution on growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →